Beta Bionics, Inc./$BBNX

1D1W1MYTD1Y5YMAX

About Beta Bionics, Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
Ticker
$BBNX
Sector
Health
Primary listing
NASDAQ
Employees
422
Headquarters
Irvine, United States
Website
www.betabionics.com

BBNX Metrics

BasicAdvanced
$753M
-
-$1.65
-
-

Bulls say / Bears say

Q2 2026 net sales rose 38% year over year to $32.0 million, while gross margin expanded to 59.0% from 53.8%; management also raised the full-year gross-margin outlook to 58.5%–59.5%. (SEC)
The pharmacy benefit plan channel is scaling rapidly: Q2 PBP sales increased 153% year over year to $11.6 million, and management expects 37%–39% of 2026 new patient starts to be reimbursed through that channel. This could broaden access and improve the commercial leverage of the iLet platform. (Beta Bionics)
Beta Bionics is building multiple medium-term growth options around its adaptive dosing technology: it initiated a pivotal U.S. trial for iLet in adults with type 2 diabetes and expects Mint, its patch-pump product, to be fully commercialized by Q2 2027, subject to FDA clearance. (Beta Bionics)
Beta Bionics remains deeply unprofitable: Q2 2026 operating loss was $25.6 million and net loss was $23.4 million, while cash, cash equivalents and investments declined to $225.2 million at June 30 from $264.7 million at year-end 2025. (SEC)
The FDA issued Beta Bionics a warning letter concerning quality-system and reporting issues identified during a 2025 facility inspection. Although the letter did not restrict current sales or manufacturing, remediation could increase costs and create regulatory or reputational risk. (Beta Bionics filing)
Several important growth catalysts remain regulatory- and execution-dependent: Mint is not yet cleared and is targeted for commercialization by Q2 2027, the type 2 diabetes indication for iLet depends on FDA clearance, and the bihormonal program requires algorithm and glucagon-formulation improvements before additional trials. (Beta Bionics)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.

BBNX News

AllArticlesVideos

BBNX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Beta Bionics (BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

Newsfile Corp2 hours ago

Did You Lose Money Investing in Beta Bionics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against BBNX

Newsfile Corp24 hours ago

BBNX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Beta Bionics (BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

Newsfile Corp2 days ago

Funds containing BBNX

Funds
Fund name
Fund size
$BBNX weighting
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.